Upper Limb Muscle Spasticity is an indication for drug development with over 10 pipeline drugs currently active. According to GlobalData, preregistered drugs for Upper Limb Muscle Spasticity have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Upper Limb Muscle Spasticity compared to historical benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Upper Limb Muscle Spasticity overview

Spasms or spasticity is a condition in which the stiffening of muscles is seen. Upper limb muscle spasticity is a motor neuron syndrome of the upper extremities. This condition causes voluntary movement impairment following stroke, spinal cord injury, and paralysis. It commonly affects elbows, arms, forearms, wrists and is characterized by muscle stiffness, impaired movement, pain, and reduced ability to relax muscles. It commonly occurs in survivors of TBI and stroke. Based on physical examination and radiographic findings diagnosis is done. Physiotherapy like stretching, and pharmacological management with BoNT-A injection and by electrical stimulation of muscles.

For a complete picture of PTSR and LoA scores for drugs in Upper Limb Muscle Spasticity, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.